In accordance with 35 U.S.C. § 287(a), the following table used in conjunction with the FDA-approved product labeling may be used to determine U.S. patents associated with the corresponding U.S. marketed product; additional patents may be pending in the U.S. and in other countries. The following list may not be all inclusive, and other products not listed here may be protected by one or more patents in the U.S. and additional countries.
ESPEROCT® [antihemophilic Factor (recombinant), GlycoPEGylated-exei] lyophilized powder for solution, for intravenous use
7,199,223
8,133,977
8,143,378
8,247,536
8,536,126
9,150,848
FIASP® (insulin aspart injection), for subcutaneous or intravenous use
6,899,699
7,762,994
8,324,157
8,579,869
8,672,898
8,684,969
8,920,383
9,108,002
9,132,239
9,457,154
9,486,588
9,616,180
9,687,611
9,775,953
9,861,757
10,220,155
10,357,616
10,376,652
D724,721
D734,450
D758,571
RE46,363
GLUCAGEN® (glucagon) for injection, for subcutaneous, intramuscular or intravenous use
no unexpired patents
LEVEMIR® (insulin detemir injection), for subcutaneous use
6,899,699
7,762,994
8,579,869
8,672,898
8,684,969
8,920,383
9,108,002
9,132,239
9,457,154
9,486,588
9,616,180
9,687,611
9,775,953
9,861,757
10,220,155
10,357,616
10,376,652
RE 46,363
D724,721
D734,450
D758,571
NORDITROPIN® (somatropin) injection, for subcutaneous use
6,899,699
7,762,994
8,579,869
8,672,898
8,684,969
8,920,383
9,108,002
9,132,239
9,457,154
9,486,588
9,616,180
9,687,611
9,775,953
9,861,757
10,220,155
10,357,616
10,376,652
RE 46,363
D729,930
D765,833
NOVOEIGHT® (antihemophilic factor, recombinant) lyophilized powder for solution, for intravenous use
6,100,061
6,475,725
6,936,441
7,094,574
8,080,414
8,084,251
8,084,252
8,329,465
8,399,620
9,982,033
NOVOLIN® 70/30 (human insulin isophane suspension and human insulin injection), for subcutaneous use
no unexpired patents
NOVOLIN® N (isophane insulin human suspension), for subcutaneous use
no unexpired patents
NOVOLIN® R (human insulin injection), for subcutaneous or intravenous use
no unexpired patents
NOVOLOG® (insulin aspart injection), for subcutaneous or intravenous use
no unexpired patents
NOVOLOG® MIX 70/30 (insulin aspart protamine and insulin aspart injectable suspension), for subcutaneous use
no unexpired patents
NOVOSEVEN® RT (coagulation Factor VIIa, recombinant) lyophilized powder for solution, for intravenous use
8,299,029
8,658,597
8,729,022
OZEMPIC® (semaglutide) injection, for subcutaneous use
6,899,699
7,762,994
8,114,833
8,129,343
8,536,122
8,579,869
8,672,898
8,684,969
8,920,383
9,108,002
9,132,239
9,457,154
9,486,588
9,616,180
9,687,611
9,775,953
9,861,757
10,220,155
10,357,616
10,376,652
RE
46,363
D724,721
D758,571
US 10,335,462
PRANDIN® (repaglinide) tablets, for oral use
no unexpired patents
REBINYN® (Coagulation Factor IX (Recombinant), GlycoPEGylated) lyophilized powder for solution for intravenous injection
7,138,371
7,416,858
7,473,680
8,404,809
8,632,770
8,791,070
RYBELSUS® (semaglutide) tablets, for oral use
8,129,343
8,536,122
9,278,123
10,086,047
10,278,923
D906,513
RYZODEG® 70/30 (insulin degludec and insulin aspart injection), for subcutaneous use
6,899,699
7,615,532
7,762,994
8,579,869
8,672,898
8,684,969
8,920,383
9,108,002
9,132,239
9,457,154
9,486,588
9,616,180
9,687,611
9,775,953
9,861,757
10,220,155
10,357,616
10,376,652
RE 46,363
D724,721
D734,450
D758,571
SAXENDA® (liraglutide) injection, for subcutaneous use
6,268,343
6,899,699
7,762,994
8,114,833
8,846,618
8,579,869
8,672,898
8,684,969
8,920,383
9,108,002
9,132,239
9,457,154
9,486,588
9,616,180
9,687,611
9,775,953
9,861,757
9,968,659
10,220,155
10,357,616
10,376,652
RE 46,363
D724,721
D734,450
D758,571
TRESIBA® (insulin degludec injection), for subcutaneous use
6,899,699
7,615,532
7,762,994
8,579,869
8,672,898
8,684,969
8,920,383
9,108,002
9,132,239
9,457,154
9,486,588
9,616,180
9,687,611
9,775,953
9,861,757
10,220,155
10,357,616
10,376,652
RE 46,363
D724,721
D734,450
D758,571
TRETTEN® Coagulation Factor XIII A-Subunit (Recombinant), for intravenous use, lyophilized powder for solution for injection
10,391,062
VAGIFEM® (estradiol vaginal tablets)
7,018,992
VICTOZA® (liraglutide) injection, for subcutaneous use
6,268,343
7,762,994
8,114,833
8,846,618
8,579,869
9,265,893
9,968,659
RE 41,956
XULTOPHY® 100/3.6 (insulin degludec and liraglutide injection), for subcutaneous use
6,268,343
6,899,699
7,615,532
7,762,994
8,579,869
8,672,898
8,684,969
8,846,618
8,920,383
8,937,042
9,108,002
9,132,239
9,457,154
9,486,588
9,616,180
9,687,611
9,775,953
9,861,757
10,220,155
10,357,616
10,376,652
RE 46,363
D724,721
D734,450
D758,571
SOGROYA® (somapacitan-beco) injection, for subcutaneous use
8,779,109
9,695,226
AUTOCOVER®
6,855,129
7,553,293
8,075,522
8,728,027
FLEXPEN®
7,762,994
8,579,869
9,265,893
RE 41,956
FLEXPRO®
6,899,699
7,762,994
8,579,869
8,672,898
8,684,969
8,920,383
9,108,002
9,132,239
9,457,154
9,486,588
9,616,180
9,687,611
9,775,953
9,861,757
10,220,155
10,357,616
10,376,652
RE 46,363
D729,930
D765,833
FLEXPRO® PENMATE®
no unexpired patents
FLEXTOUCH®
6,899,699
7,762,994
8,579,869
8,672,898
8,684,969
8,920,383
9,108,002
9,132,239
9,457,154
9,486,588
9,616,180
9,687,611
9,775,953
9,861,757
10,220,155
10,357,616
10,376,652
RE 46,363
D724,721
D734,450
D758,571
NOVOFINE® 32G
no unexpired patents
NOVOFINE® PLUS 32G
no unexpired patents
NOVOPEN® ECHO®
6,663,602
7,241,278
10,245,383
NOVOTWIST®
7,654,986
7,762,994
8,137,325
8,579,869
D675,316
PENFILL®
no unexpired patents
PENFILL® Cartridge
7,762,994
8,579,869